Auro Laboratories FY26: Revenue Nearly Doubled Off a Wrecked Base, and the Multiple Sits at 45x

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Auro Laboratories closed FY26 with sales of ₹30.74 crore, up 58% from the ₹19.40 crore it managed in FY25. That is a genuine rebound — and also a reminder that FY25 was the year the factory was largely switched off. Two years earlier, in FY24, this same company did ₹53.64 crore. So the “growth” story and the “what happened” story are the same story.

Net profit for the year was ₹3.53 crore, against ₹1.84 crore the year before. The market values the whole enterprise at ₹158 crore and pays roughly 45x earnings for it, while ROCE sits at 9.42% and ROE at 8.15% — single-digit returns wearing a mid-forties multiple.

Underneath, borrowings climbed to ₹63.30 crore from ₹42.72 crore, inventory more than tripled to ₹13.54 crore, and finance costs quadrupled to ₹4.25 crore. A small API maker in the middle of a large-for-its-size expansion, in other words, with the balance sheet doing most of the talking.

The question the rest of this entry circles: what does a 45x multiple see in a business whose five-year sales record compounds at −11%?

2 — Introduction

Auro Laboratories was incorporated in 1989 and makes generic Active Pharmaceutical Ingredients out of a single plant at Tarapur, Maharashtra. The flagship molecule is Metformin Hydrochloride, the first-line treatment for type 2 diabetes, alongside Chlorphenamine Maleate and Chlorzoxazone. Roughly 80% of revenue has historically come from Metformin, and the bulk of sales ships overseas — the credit assessment puts exports at about 85% of revenue, with Europe the main market.

The recent past has been dominated by one thing: a debt-funded brownfield expansion. The rating report notes a roughly nine-month disruption to operations while the new block was integrated, which is what turned FY25’s revenue into a crater. The new capacity was commissioned in August 2025, lifting installed capacity from 1,260 MT to 2,100 MT per year, and the company is separately building a forward-integration unit to make tablets from its own APIs.

Two more recent items sit on the record: a WHO GMP certificate for the Tarapur plant in November 2025, valid to September 2028, and — as ever with this company — a reshuffle in the finance function, covered later.

3 — Business Model: WTF Do They Even Do?

Auro buys chemical inputs, mostly from overseas vendors, and converts them into Metformin HCL powder that other companies turn into diabetes tablets. It is, functionally, a one-molecule export shop with two smaller molecules keeping it company on the product list.

This is a commodity API in a fragmented, ferociously competitive segment. The rating agency is blunt about the position: modest scale, limited pricing power against larger domestic and global players, and profitability that swings with raw-material prices and the rupee. Auro hedges some of the forex through natural hedging and forward contracts; the rest it simply lives with.

The concentration cuts both ways. Metformin is an essential medicine with year-round global demand, which is why a tiny Tarapur plant can ship to Europe at all. But one molecule doing ~80% of revenue means one molecule’s pricing cycle is roughly the whole business’s pricing cycle. There is no second leg to stand on when the first one wobbles — and in FY25, when the plant was down for its rebuild, there was no leg at all.

The forward-integration plan into tablets is the attempt to add that second leg: instead of selling powder to a formulator, sell the finished tablets, supported by a proposed arrangement with a European customer. The unit is designed for 750 million tablets a year. Whether that changes the economics or just adds a bigger loan is the open question the balance sheet keeps raising.

Does a WHO GMP stamp and a European tablet contract change what a single-molecule commodity shop fundamentally is — or just extend its reach?

4 — Financials Overview

Figures are standalone, in ₹ crore.

The March quarter did ₹9.83 crore, up 33% on the year-ago quarter and 5% on the prior one — the top line has clearly